Format

Send to

Choose Destination
J Am Coll Cardiol. 2019 Mar 5;73(8):948-963. doi: 10.1016/j.jacc.2018.11.050.

Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review.

Author information

1
Department of Internal Medicine, Emory University School of Medicine, Atlanta, Georgia.
2
Emory Clinical Cardiovascular Research Institute, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia.
3
Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana.
4
Emory Clinical Cardiovascular Research Institute, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia. Electronic address: lsperli@emory.edu.

Abstract

Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) are both manifestations of end-organ damage of the metabolic syndrome. Through multiple pathophysiological mechanisms, CVD and NAFLD are associated with each other. Systemic inflammation, endothelial dysfunction, hepatic insulin resistance, oxidative stress, and altered lipid metabolism are some of the mechanisms by which NAFLD increases the risk of CVD. Patients with NAFLD develop increased atherosclerosis, cardiomyopathy, and arrhythmia, which clinically result in cardiovascular morbidity and mortality. Defining the mechanisms linking these 2 diseases offers the opportunity to further develop targeted therapies. The aim of this comprehensive review is to examine the association between CVD and NAFLD and discuss the overlapping management approaches.

KEYWORDS:

cardiovascular disease; metabolic syndrome; nonalcoholic fatty liver disease

PMID:
30819364
DOI:
10.1016/j.jacc.2018.11.050

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center